Autologous haematopoietic stem cell transplant is a specialized procedure that uses a patient’s own stem cells to rebuild blood-making capacity after intensive treatment for certain blood cancers and severe autoimmune conditions. This approach offers unique advantages and challenges, with carefully orchestrated steps from cell collection through recovery, and a growing body of research exploring how to optimize outcomes and expand its use to new patient groups.

When Your Own Cells Become Medicine: The Core Approach to Stem Cell Treatment

Autologous haematopoietic stem cell transplant, often shortened to aHSCT or autologous transplant, represents a treatment strategy in which doctors collect healthy blood stem cells from a patient, store them safely, and then return them after the patient receives very strong doses of chemotherapy or radiation. The word “autologous” simply means that the cells come from your own body, not from another person. This distinguishes the procedure from allogeneic transplants, where stem cells are donated by a sibling, unrelated volunteer, or cord blood source.^[1]

The core idea behind this treatment is straightforward but powerful. Many blood cancers and certain autoimmune diseases require aggressive therapy to destroy the harmful cells causing the condition. However, these high-dose treatments also damage or destroy the bone marrow, the spongy tissue inside bones where blood cells are normally made. Without functioning bone marrow, the body cannot produce the red blood cells that carry oxygen, the white blood cells that fight infection, or the platelets that help blood clot. By rescuing a patient’s own healthy stem cells before treatment and returning them afterward, doctors can restore the bone marrow’s ability to produce blood cells and allow patients to recover from treatment that would otherwise be impossible to survive.^[5]

Using a patient’s own cells offers several important advantages. There is no risk of incompatibility between the transplanted cells and the patient’s body, which means there is no danger of graft-versus-host disease, a serious complication that occurs when donor immune cells attack the recipient’s tissues. This makes autologous transplants safer in some ways than allogeneic procedures. Additionally, patients do not need to wait to find a matching donor, which can be a lengthy and sometimes unsuccessful process.^[1]

The procedure is primarily used for blood cancers. More than half of all autologous transplants worldwide are performed for multiple myeloma, a cancer of plasma cells in the bone marrow, and non-Hodgkin lymphoma, a cancer of the lymphatic system. It is also used to treat Hodgkin lymphoma when other treatments have not worked or when the disease returns after initial treatment. In addition to cancer, autologous stem cell transplant has shown promise in treating severe, treatment-resistant autoimmune diseases such as multiple sclerosis, systemic sclerosis, and Crohn’s disease, though this use is less common and often considered when all other options have been exhausted.^[2][6]

The treatment is considered when the disease is severe and has either not responded to standard therapies or has come back after initial success. Autologous transplant is typically not the first treatment offered but rather a powerful tool held in reserve for situations where the disease is aggressive or has proven resistant to other approaches. Research has shown that while this procedure may not cure all cancers, it can achieve long-term remission, meaning patients can live symptom-free without detectable signs of disease for extended periods.^[5]

Standard Treatment: The Journey from Collection to Recovery

The autologous transplant process unfolds in several carefully planned stages, each critical to success. The journey begins well before any cells are collected, with a thorough evaluation of the patient’s overall health. Because high-dose chemotherapy places significant stress on the body and increases the risk of serious infections, doctors need to confirm that the patient’s heart, lungs, liver, kidneys, and other vital organs are strong enough to withstand the treatment. This evaluation typically includes an electrocardiogram (a test that records the heart’s electrical activity), an echocardiogram (an ultrasound of the heart), computed tomography (CT) scans, blood tests to check organ function, and sometimes a biopsy to examine cancer cells in detail.^[5]

Before stem cells can be collected, patients receive medications called growth factors, which are hormone-like substances that stimulate the bone marrow to produce more blood stem cells than usual. Additional drugs are given to encourage these cells to leave the bone marrow and enter the bloodstream, a process doctors call mobilization. This preparation typically takes several days.^[5]

The actual collection of stem cells is done through a process called apheresis. During apheresis, blood is drawn from the patient through a tube connected to a special machine that separates and collects the stem cells while returning the rest of the blood back to the patient through another tube. The process is not painful, though it can be time-consuming, often lasting three to four hours. Multiple collection sessions may be needed over several days to gather enough stem cells for transplantation. Once collected, the stem cells are carefully processed, counted, and frozen in special preservatives for storage until they are needed.^[5]

The next phase is called conditioning, during which patients receive high-dose chemotherapy, and sometimes radiation therapy, to destroy cancer cells and create space in the bone marrow for the new stem cells. This conditioning period typically lasts between seven and fourteen days. The goal is to eliminate as many cancer cells as possible while also suppressing the immune system enough to allow the transplanted cells to settle in and begin working. Conditioning regimens vary depending on the type and stage of disease, the patient’s age, and overall health status. Some regimens are myeloablative, meaning they completely destroy the bone marrow, while others are nonmyeloablative or “reduced-intensity,” using lower doses that cause less damage to the bone marrow but still achieve therapeutic goals.^[6]

Following conditioning, the frozen stem cells are thawed and infused back into the patient’s bloodstream through the central line in a process that resembles a simple blood transfusion. The stem cells naturally find their way back to the bone marrow, where they begin the work of producing new blood cells. This moment is referred to as “Day 0” in transplant terminology, and all subsequent recovery milestones are measured from this date.^[6]

After the stem cell infusion, patients enter a critical period where their blood counts drop to very low levels because the conditioning treatment has destroyed most of the existing bone marrow cells and the transplanted stem cells have not yet begun producing new cells in significant numbers. This phase, called the neutropenic phase, typically lasts between ten and fourteen days and is the most dangerous time because the patient has almost no white blood cells to fight off infections. During this period, patients are at extremely high risk for bacterial, viral, and fungal infections, and even minor illnesses can become life-threatening.^[6]

To protect patients during this vulnerable time, doctors prescribe antibiotics, antiviral medications, and antifungal drugs as preventive measures. Patients may remain in the hospital during the neutropenic phase, though some transplant centers now perform autologous transplants on an outpatient basis for carefully selected patients who can be closely monitored and have strong support at home. Those who remain hospitalized typically stay in specialized transplant units with strict infection control measures, including filtered air systems and limited visitor access.^[5]

The milestone everyone waits for is called engraftment, the moment when the transplanted stem cells have settled into the bone marrow and begun producing enough new blood cells to be detected in routine blood tests. Engraftment typically occurs between two and four weeks after the stem cell infusion. Doctors monitor blood counts daily to watch for the first signs of recovery, particularly looking for rising numbers of white blood cells called neutrophils, which are the body’s primary defense against bacterial infections. Once engraftment occurs and blood counts begin to recover, the risk of serious infection gradually decreases, though patients remain vulnerable for many months.^[6]

The recovery period extends well beyond engraftment. Even after blood counts return to safe levels, patients may experience ongoing side effects from the high-dose chemotherapy. Common problems include fatigue, nausea, mouth sores, diarrhea, loss of appetite, and hair loss. Many patients also develop skin rashes, particularly if they used different detergents or were exposed to new substances during their hospitalization. The immune system takes many months to fully rebuild, with some immune functions not returning to normal for a year or longer. During this extended recovery, patients must continue taking infection prevention measures, including avoiding crowds, staying away from people who are sick, and being careful with food preparation to avoid foodborne illnesses.^[5]

Patients typically need regular follow-up appointments after leaving the hospital, sometimes as frequently as weekly at first, gradually decreasing to monthly and then less often as recovery progresses. These appointments allow doctors to monitor blood counts, watch for complications, adjust medications, and provide supportive care. Many patients also need blood or platelet transfusions during the early recovery period to maintain safe levels while their bone marrow continues rebuilding its capacity. Any blood products given after autologous transplant must be specially treated with radiation (irradiated) to prevent a rare but serious reaction, and patients carry a card documenting this requirement for about a year after transplant.^[20]

Full recovery from an autologous stem cell transplant is a gradual process. Most patients begin to feel significantly better within three to six months, but it may take a full year or even longer before they truly feel they have returned to their pre-illness level of health and energy. Physical rehabilitation, nutritional support, and psychological counseling are often important components of the recovery process, helping patients regain strength, maintain proper nutrition despite ongoing side effects, and cope with the emotional challenges of serious illness and intensive treatment.^[18]

Treatment in Clinical Trials: Advancing the Science of Stem Cell Transplantation

While autologous stem cell transplant is now a well-established treatment for certain blood cancers, researchers continue to explore ways to make the procedure safer, more effective, and applicable to a broader range of conditions. Clinical trials are currently investigating new approaches across multiple fronts, from refining the conditioning regimens to developing better supportive care strategies and expanding the use of transplant to new patient populations.

One major area of investigation focuses on reducing the toxicity of conditioning regimens while maintaining their effectiveness. Traditional high-dose chemotherapy can cause significant damage to organs beyond the bone marrow, including the heart, lungs, liver, and kidneys. Researchers are testing reduced-intensity conditioning protocols that use lower doses of chemotherapy or different drug combinations to achieve cancer control with fewer side effects. These gentler approaches may be particularly valuable for older patients or those with pre-existing organ problems who cannot safely tolerate standard high-dose conditioning. Early-phase clinical trials are examining various drug combinations and dosing schedules to identify the optimal balance between cancer elimination and toxicity reduction.^[6]

Another promising area of research involves manipulating the collected stem cells before they are frozen and later reinfused. Scientists are exploring techniques to purify the stem cell product, removing any contaminating cancer cells that might have been collected along with the healthy stem cells. This ex vivo purging, or cleaning of the stem cell product outside the body, might reduce the risk of cancer relapse by ensuring that only healthy cells are returned to the patient. Various methods are being tested, including using antibodies that bind to cancer cells and mark them for removal, or treating the collected cells with chemotherapy drugs before freezing them.^[6]

For autoimmune diseases, clinical trials are examining how autologous stem cell transplant can be used to essentially “reset” the immune system. The theory is that by destroying the existing immune cells with conditioning chemotherapy and then rebuilding the immune system from stem cells, doctors can eliminate the harmful immune cells that were attacking the patient’s own tissues. European research groups, particularly through the European Society for Blood and Marrow Transplantation, have been leaders in this field, conducting trials in multiple sclerosis, systemic sclerosis, Crohn’s disease, and other severe autoimmune conditions. Results from several Phase II and Phase III trials have shown that carefully selected patients with aggressive, treatment-resistant autoimmune disease can achieve sustained remission or significant improvement after autologous transplant.^[2][11]

Recent consensus recommendations from the European Committee for Treatment and Research in Multiple Sclerosis and the European Society for Blood and Marrow Transplantation have provided detailed guidance on using autologous stem cell transplant for multiple sclerosis and neuromyelitis optica spectrum disorder. These recommendations outline specific patient selection criteria, optimal conditioning regimens, and monitoring protocols. The trials that informed these recommendations showed that autologous transplant can be particularly effective for patients with relapsing forms of multiple sclerosis that have not responded to high-efficacy disease-modifying therapies. Some studies even suggest that transplant might be considered earlier in the disease course for patients with rapidly evolving, severe disease, though this remains an area of active debate and ongoing research.^[11]

Researchers are also investigating whether autologous transplant can benefit patients with progressive forms of multiple sclerosis, where the disease steadily worsens without distinct relapses. This is a more challenging question because progressive disease may be driven by different biological mechanisms than relapsing disease, and it’s less clear whether immune system resetting would be helpful. Clinical trials are carefully tracking outcomes in these patients to determine whether there is a role for transplant in progressive disease.^[11]

Studies are also examining ways to improve supportive care and reduce complications during and after transplant. Research teams are testing new antimicrobial strategies to prevent infections, developing better approaches to managing side effects like mucositis (painful mouth sores), and investigating medications that might speed engraftment or reduce the duration of the neutropenic phase. Some trials are exploring the use of growth factors given after stem cell infusion to accelerate blood count recovery, potentially shortening hospital stays and reducing infection risk.

The optimal timing of autologous transplant in treatment sequences is another important research question. For multiple myeloma, which accounts for a large proportion of autologous transplants, ongoing trials are comparing immediate transplant after initial chemotherapy versus delaying transplant until the disease relapses. Some studies suggest that early transplant may provide better long-term outcomes, while others indicate that with modern drug therapies, it may be reasonable to save transplant for later if initial treatment works well. These trials are conducted primarily in Europe and the United States, with results helping to refine international treatment guidelines.

Worldwide, approximately 90,000 stem cell transplants are performed each year, with about 53% being autologous procedures. The number of transplants continues to increase by 10 to 20 percent annually as techniques improve and outcomes get better. Reductions in organ damage, infection rates, and other serious complications are contributing to improved survival and quality of life for transplant recipients.^[6]

Clinical trials are available at major transplant centers throughout the world. Eligibility for trials typically depends on factors such as the type and stage of disease, previous treatments received, age, and overall health status. Patients interested in participating in a clinical trial should discuss options with their transplant doctor, who can help identify appropriate studies and explain the potential benefits and risks of trial participation compared to standard treatment approaches.

Most common treatment methods

• Stem cell mobilization and collection
  • Administration of growth factor medications to increase stem cell production in bone marrow
  • Use of additional drugs to move stem cells from bone marrow into bloodstream
  • Apheresis procedure to collect stem cells from circulating blood over three to four hours
  • Processing, counting, and cryopreservation of collected stem cells for future use
• Conditioning therapy
  • High-dose chemotherapy over seven to fourteen days to eliminate cancer cells and create space in bone marrow
  • Myeloablative regimens that completely destroy existing bone marrow function
  • Reduced-intensity or nonmyeloablative regimens using lower drug doses with less organ toxicity
  • Radiation therapy in selected cases as part of conditioning treatment
• Stem cell infusion and engraftment support
  • Thawing and intravenous infusion of previously collected stem cells on Day 0
  • Daily monitoring of blood counts to detect early signs of engraftment
  • Growth factor medications after infusion to potentially accelerate blood count recovery
  • Blood and platelet transfusions during the neutropenic phase to maintain safe levels
  • Special irradiation of all blood products to prevent transfusion reactions
• Infection prevention and antimicrobial therapy
  • Prophylactic antibiotics to prevent bacterial infections during neutropenic phase
  • Antiviral medications to protect against viral reactivation and infection
  • Antifungal drugs to prevent serious fungal infections
  • Environmental precautions including filtered air systems and visitor restrictions
  • Ongoing infection prevention measures at home for many months after transplant
• Supportive care during recovery
  • Management of chemotherapy side effects including nausea, mouth sores, and diarrhea
  • Nutritional support to maintain adequate caloric intake during periods of poor appetite
  • Physical rehabilitation to help patients regain strength and endurance
  • Regular follow-up appointments initially weekly, then gradually less frequent
  • Psychological counseling to address emotional challenges of intensive treatment